Haemophilia Treatment Market to Grow with a CAGR of 5.74% through 2029
Increasing prevalence of hemophilia and surging trend
of prophylaxis treatment is expected to drive the Global Haemophilia Treatment
Market growth in the forecast period, 2025-2029.
According to TechSci Research report, “Haemophilia
Treatment Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2029”, the Global Haemophilia Treatment
Market stood at USD 11.38 Billion in 2023 and is anticipated to grow with a
CAGR of 5.74% in the forecast period, 2025-2029. The increase in research and
development studies focused on treatment therapies, along with the growing
target population and diagnosis rate, are key factors driving the growth of the
hemophilia treatment market.
Additionally, the rise in the use of prophylactic
treatment for hemophilia contributes to this growth.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Haemophilia Treatment Market”
The growing global initiatives by government and
non-government organizations to raise awareness about hemophilia drugs are key
factors driving the market growth. The increasing adoption of prophylactic
treatment is also expected to contribute to the demand for hemophilia.
Treatment involves regular replacement of clotting factors, and alternative
therapies without clotting factors are also being utilized.
The haemophilia market is experiencing growth due to
factors such as increased healthcare expenditure, preference for prophylactic
treatment, higher diagnosis rates, and significant usage of recombinant
coagulation factor. In the near future, recombinant coagulation factor
concentrates are projected to dominate the global haemophilia market.
Physicians prefer recombinant coagulation factor, which is anticipated to drive
the haemophilia market in the forecast period due to its lower risk of
bloodborne infection. On the other hand, plasma-derived coagulation factor is
expected to have a slower CAGR during the forecast period due to a higher risk
of blood-associated infections and limited availability of plasma derived from
blood.
The availability of limited treatment therapy options
and the increasing responsibility of regulatory authorities to address
treatment have led to increased research and development efforts. Both public
and commercial healthcare organizations are investing significantly in
specialized clinics to meet the specific demands of patients. The number of
Hemophilia treatment centers is increasing to provide treatment to
underprivileged individuals. Authorities emphasize that individuals with
Hemophilia receive treatment at specialized facilities for optimal care and
health education. The construction of healthcare centers is expected to fuel
the growth of the Hemophilia Market.
One of the primary drivers of haemophilia market
growth is the increasing prevalence of haemophilia, which is driving the demand
for treatment options. Patients with severe haemophilia require frequent
treatment to maintain sufficient clotting factors and prevent bleeding.
According to the Centers for Disease Control and Prevention, Hemophilia A
affects 1 in every 5,000 male births in the United States. As the number of
dependent patients requiring comprehensive care continues to rise, this
significant prevalence is expected to have a substantial impact on the market.
Moreover, patients receiving quality care are more likely to have fewer
co-morbidities and a reduced risk of severe bleeding. Thus, the increasing
number of patients with haemophilia has led to a higher demand for haemophilia
therapy, resulting in increased product adoption rates.
The Global Haemophilia Treatment Market is segmented
into type, product, treatment, therapy, regional distribution, and company.
Based on type, Hemophilia A is projected to maintain a
significant market share throughout the forecast period. It is the most
prevalent severe bleeding disorder. Replacement therapy, which involves
providing the missing coagulation factor, has been the primary treatment
approach for both prophylaxis and bleeding management.
According to the data published by the World
Federation of Hemophilia in 2021, hemophilia A primarily affects males, accounting
for 146,246 cases (88%), followed by females with 5,636 cases (3%), and cases
where the sex is unknown, totaling 9,917 (6%). The primary medication used for
treating hemophilia A is a concentrated FVIII product, also known as clotting
factor. Advances in recombinant protein engineering, gene therapy, and novel
strategies targeting the coagulation cascade have enabled the development of
recombinant factor products in the laboratory, reducing reliance on
human-derived pools of donor-sourced plasma. For example, in December 2021,
Pfizer Inc. and Sangamo Therapeutics, Inc., a genomic medicines company,
released updated follow-up data from the Phase 1/2 Alta study of giroctocogene
fitelparvovec, an investigational gene therapy for patients with moderately
severe to severe hemophilia A. The increasing focus on gene therapies for
Hemophilia A is expected to drive the growth of this segment.
Based on region, North America segment is expected to
grow during the forecast period. Among all regions, North America
dominates the market with the largest market share during the forecast period.
The initial drivers of regional development include the increasing prevalence
and propensity for preventative medicine. In the United States, this condition
is often diagnosed early in life. The growth of the hemophilia market in the
region is driven by therapeutic advances in hemophilia, leading to the approval
of new agents by the Food and Drug Administration, increasing awareness of
technologically advanced products, rising prevalence of hemophilia, and a large
patient pool.
The increasing research on gene therapies and
favorable outcomes are expected to drive market growth in the United States. On
the other hand, Asia-Pacific is expected to experience significant growth during
the forecast period. Factors such as increased per capita use of medications
for factor VIII and IX deficiencies and early disease detection in countries
like Japan, India, Indonesia, and Malaysia contribute to this growth.
Major companies operating in Global Haemophilia
Treatment Market are:
- Bayer AG
- BioMarin
Pharmaceutical, Inc.
- CSL Behring LLC
- Kedrion S.p.A
- Novo Nordisk
A/S
- Pfizer, Inc.
- Octapharma AG
- Sanofi SA
- Takeda
Pharmaceutical Company Limited
- Grifols S.A.
Download Free Sample Report
Customers can also request for 10% free customization
on this report
“The growing number of hemophilic patients and the
increasing prevalence of genetic abnormalities worldwide are key factors that
positively impact the market. Moreover, the rising diagnosis rate of the
disease and the growing adoption of prophylactic treatment for hemophilia
present profitable growth opportunities for leading market players.
Furthermore, government agencies in various countries are organizing extensive
awareness campaigns to promote early diagnosis and appropriate screening
procedures for neonates, thereby creating a positive market outlook.
Additionally, substantial investments in research and development (R&D)
activities are being made due to the limited availability of treatment options.
Notably, industry leaders are focused on introducing advanced diagnostic tools
and therapies to enhance the effectiveness and precision of hemophilia
treatment, further contributing to a favorable market landscape. Additionally,
significant investments are being made to expand the establishment of
specialized hemophilia treatment centers (HTCs) globally, which is expected to
drive market growth.,” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“Haemophilia Treatment Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, Segmented By Type
(Haemophilia A, Haemophilia B, Haemophilia C), By Product (Recombinant
Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrate,
Desmopressin, Antifibrinolytics Agents), By
Treatment (On-demand and Prophylaxis), By
Therapy (Replacement Therapy, ITI therapy and Gene Therapy), By Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global
Haemophilia Treatment Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Haemophilia
Treatment Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com